Source - LSE Regulatory
RNS Number : 0606M
ReNeuron Group plc
16 September 2021
 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Result of AGM

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.

 

The voting results will be made available on the 'Investors' section of the Company's website shortly:

http://www.reneuron.com/investors/general-meeting/

 

ENDS

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

 

 

 

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

 

Stefano Aquilino (Sales & Corporate Broking)

 

 

 

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUNUVRAVUKAAR
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Reneuron Group PLC (RENE)

-0.08p (-2.17%)
delayed 05:00AM